Cummings Condemns Jordan’s Effort to Obstruct Drug Pricing Investigation

Apr 17, 2019
Press Release

Washington, D.C. (Apr. 17, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, sent a letter to Ranking Member Jim Jordan in response to unprecedented letters Jordan sent to 12 companies urging them not to cooperate with the Committee’s ongoing investigation into the skyrocketing prices of prescription drugs.

“You personally may have no interest in bringing down drug prices for your constituents, you honestly may believe it is more important to protect drug company profits and stock prices than the budgets of American families, and you may even disagree with President Trump that drug companies are ‘getting away with murder’, but your efforts to interfere with this investigation represent a new low for a Member of this Committee,” Cummings wrote.

“It is one thing to have an honest disagreement about the Committee’s policy or approach—which would command respect—but it is quite another to actively obstruct an investigation in the service of placing corporate interests over those of the American people,” Cummings added.

Cummings noted that Jordan had professed concern with the Committee’s commitment to safeguarding sensitive documents, but Jordan failed to mention that he was the one blocking a protocol to protect such documents.

Cummings launched the Committee’s wide-ranging investigation in January, and companies have been cooperating with the review.

According to a recent Kaiser Family Foundation poll, 79 percent of Americans believe the cost of prescription drugs is unreasonable and only 25 percent of Americans trust drug companies to price their products fairly.  

Click here to read today’s letter.


116th Congress